He routinely counsels biotechnology and pharmaceutical companies of all sizes in developing their patent claiming and filing strategies, procuring patents on cornerstone technologies, and strategically managing patent portfolios to maximize investments. Ken also counsels lenders and investors in assessing the value of patent assets through due diligence reviews, including validity analyses, freedom to operate analyses, and in-licensed technology investigations. In addition to patent procurement counseling, he represents pharmaceutical companies in high-stakes patent litigations involving challenges under the Hatch-Waxman Act.